Our paper has been published in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. Mario A Parra MD PhD, Juan Granada MD, gerardo fernandez PhD, et al. (2022). In a 40-month prospective study, ViewMind showed:

Highlights:

• A biomarker to 'prospectively' predict Alzheimer's Disease with high accuracy. PPV 94% and NPV 100%

• Ability to very accurately differentiate cognitive decline due to aging versus a dementia

• 100% correlation between the prospective prediction and an independent clinical diagnosis (blinded)

• Biomarker is based on ocular movements and AI and works independently of culture, age, and education

• A scalable, non-invasive, and cost-effective method to pre-screen at-risk populations for inclusion in Amyloid-Beta or Tau inhibitor therapeutic clinical studies or use in the clinical setting

© Copyright Viewmind 2018 - 2023 | All rights reserved